Pain – Opioids

  • Zohydro ER 2017 report

    Zohydro ER 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 28 Pages The 5 Key Questions Addressed by this...

  • Abstral 2016 report

    Abstral 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 28 Pages The 5 Key Questions Addressed by this Report:...

  • Belbuca 2016 report

    Belbuca 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 30 Pages The 5 Key Questions Addressed by this Report:...

  • Butrans 2016 report

    Butrans 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 28 Pages The 5 Key Questions Addressed by this Report:...

  • Conzip 2016 report

    Conzip 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 32 Pages The 5 Key Questions Addressed by this Report:...

  • Embeda 2016 report

    Embeda 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 30 Pages The 5 Key Questions Addressed by this Report:...

  • Fentanyl Patch 2016 report

    Fentanyl Patch 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 26 Pages The 5 Key Questions Addressed by this...

  • Fentora 2016 report

    Fentora 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 24 Pages The 5 Key Questions Addressed by this Report:...

  • Hysingla ER 2016 report

    Hysingla ER 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 28 Pages The 5 Key Questions Addressed by this...

  • Lazanda 2016 report

    Lazanda 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 28 Pages The 5 Key Questions Addressed by this Report:...

  • Levorphanol 2016 report

    Levorphanol 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 30 Pages The 5 Key Questions Addressed by this Report:...

  • Nucynta 2016 report

    Nucynta 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 30 Pages The 5 Key Questions Addressed by this Report:...